JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fulton, D.
Right arrow Articles by Quilley, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fulton, D.
Right arrow Articles by Quilley, J.

Vol. 286, Issue 3, 1146-1151, September 1998

Evidence against Anandamide as the Hyperpolarizing Factor Mediating the Nitric Oxide-Independent Coronary Vasodilator Effect of Bradykinin in the Rat1

David Fulton and John Quilley

Department of Pharmacology and Molecular Cardiobiology Division, Boyer Center for Molecular Medicine, Yale University, New Haven, Connecticut (D.F.) and Department of Cell Biology, UMDNJ-SOM, Stratford, New Jersey (J.Q.)

The mediator of nitric oxide-(NO) independent vasodilation attributed to endothelium-derived hyperpolarizing factor remains unidentified although there is evidence for a cytochrome P450-derived eicosanoid. Anandamide, the ethanolamide of arachidonic acid and an endogenous ligand for cannabinoid receptors, was proposed as an endothelium-derived hyperpolarizing factor-mediating mesenteric vasodilation to acetylcholine and the hypotensive effect of bradykinin. Using pharmacological interventions that attenuate responses to bradykinin, we examined the possibility of anandamide as a mediator of the NO-independent vasodilator effect of bradykinin in the rat perfused heart by determining responses to anandamide and arachidonic acid. Hearts were treated with indomethacin to exclude prostaglandins and nitroarginine to inhibit NO synthesis and elevate perfusion pressure. The cannabinoid receptor antagonist, SR 141716A (2 µM), reduced dose-dependent vasodilator responses to anandamide (1-10 µg) but was without effect on responses to AA (1-10 µg), bradykinin (10-1000 ng) or cromakalim (1-10 µg). Inhibition of voltage-dependent Ca++ channels with nifedipine (5 nM) attenuated vasodilation to anandamide and arachidonic acid whereas inhibition of Ca++-activated K+ channels with charybdotoxin (10 nM) reduced responses to arachidonic acid but had no effect on vasodilation induced by anandamide. Inhibition of cytochrome P450 with clotrimazole (1 µM) greatly reduced vasodilator responses to bradykinin with less effect on those to anandamide. Finally, the time course of the coronary vasodilator responses to anandamide and bradykinin were dissimilar. These results argue against a role of anandamide in the vasodilator effect of bradykinin in the rat heart.


0022-3565/98/2863-1146$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
B. Vanheel and J. Van de Voorde
Regional Differences in Anandamide- and Methanandamide-Induced Membrane Potential Changes in Rat Mesenteric Arteries
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 322 - 328.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
Y. Qiu and J. Quilley
Vascular effects of arachidonic acid in the rat perfused heart: role of the endothelium, cyclooxygenase, cytochrome P450, and K+ channels
J. Lipid Res., December 1, 1999; 40(12): 2177 - 2184.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.